The next generation of hepatitis C treatments is coming. This webpage summarizes these possible hep C treatments, treatments that are currently within the early stages of clinical trials. These treatments may or may not be successfully approved for use and, if they are approved, may take a number of years to do so.
If you are looking for information about hep C treatments further along in the drug approval process, please check out our Hep C Drug Pipeline Treatments page. But, if you are looking for information about currently approved hep C treatments, look for their pages in the drop-down menu under BC’s PharmaCare Covered Treatments or check out our Treatment Coverage Across Canada page.
Treatments in the Early Stages of Clinical Trials
| Pharmaceutical Companies | Treatments | Currently Targeted Genotypes |
| AbbVie | ABT-493 / ABT-530 | 1-6 |
| Enanta | EDP-494 | 1,3 |
| Gilead | Sofosbuvir / Velpatasvir + GS-9857* | 1-6 |
| Janssen | AL-335 + Odalasvir (ACHN-3102) + Simeprevir | 1-6 |
| Merck | Grazoprevir (MK-5172) and MK-3682 with Elbasvir (MK-8742) or MK-8408 | 3-6 |
| Regulus | RG-101 | All |
| *GS-9857’s generic name is voxilaprevir. | ||
Maker: AbbVie
Treatment: ABT-493 / ABT-530
Targeted Genotype: 1-6
Treatment Description: ABT-493 / ABT-530 is made up of 2 direct-acting antivirals, ABT-493, a NS3/4A protease inhibitor, and ABT-530, a NS5A inhibitor, This treatment is achieving good clinical trial results without having to be combined with ribavirin.
- ABT-493 / ABT-530
Approximate Sustained Viral Response (SVR)/”Cure Rate”: 100%
Possible Daily Dose: 1 pill
Possible Length of Treatment: 8 or 12 weeks
Common Side Effects Reported in Clinical Trials:
- Diarrhea
- Headache
- Tiredness (fatigue)
Steps in Drug Approval Pipeline: Step 1 – Testing
Additional Information:
- Digestive Disease Week 2016 in San Diego Part II
-
Investigative Combo ABT-493 plus ABT-530 – Succeeds Against Multiple HCV Genotypes
Maker: Enanta
Treatment: EDP-494
Targeted Genotypes: 1, 3
Treatment Description: EDP-494, a Cyclophilin Inhibitor, targets a patient’s cyclophilin, a protein that is essential for replication of the hep C virus. As it targets different virus elements, it is hoped that it will cure patients resistant to direct-acting antiviral hep C therapies. The plan is to combine it with a DAA.
- EDP-494 +
- DAA
Steps in Drug Approval Pipeline: Step 1 – Testing
Additional Information:
- Enanta Pharmaceuticals Initiates Proof-of-Concept Study with Pan-genotypic Cyclophilin Inhibitor EDP-494 in Patients with Genotype 1 or Genotype 3 Chronic Hepatitis C Virus
Maker: Gilead
Treatment: Sofosbuvir / Velpatasvir / GS-9857
Targeted Genotypes: 1 – 6
Treatment Description: Sofosbuvir / Velpatasvir / GS-9857 is made up of 3 direct-acting antivirals. GS-9857’s generic name is voxilaprevir.
- Sovaldi +
- Velpatasvir +
- GS-9857 (Voxilaprevir)
Approximate Sustained Viral Response (SVR)/”Cure Rate”: 85 – 100% depending on the virus’ genotype and the patient’s health
Possible Daily Dose: 1 pill
Possible Length of Treatment: 6 – 12 weeks
Common Side Effects Reported in Clinical Trials:
- Diarrhea
- Headache
- Nausea
- Tiredness (fatigue)
Steps in Drug Approval Pipeline: Step 1 – Testing
Additional Information:
- Sofosbuvir/velpatasvir + GS-9857 for 8 weeks cures hepatitis C for most people with genotype 1 or 3
-
Sofosbuvir/velpatasvir + GS-9857 works well for treatment-experienced hepatitis C patients
Maker: Janssen
Treatment: AL-335 + Odalasvir (ACHN-3102) + Simeprevir
Targeted Genotype: 1-6
Treatment Description: AL-335 is a nucleotide polymerase inhibitor and odalasvir (ACHN-3102) is a NS5A inhibitor. Simeprevir (brand name Galexos) is a NS3/4A protease inhibitors. These inhibitors work by blocking viral enzymes (protease) that enables the hep C virus to survive and replicate in host cells.
- AL-335 +
- Odalasvir (ACHN-3102) +
- Simeprevir (brand name Galexos)
Possible Daily Dose: 1 pill
Step in Drug Approval Pipeline: Step 1 – Testing
Additional Information:
-
Janssen to Unveil New Hepatitis B and C Data at The International Liver Congress™ 2016 of the European Association for the Study of the Liver (EASL)
Maker: Merck
Treatment: Grazoprevir (MK-5172) and MK-3682 with Elbasvir (MK-8742) or MK-8408
Possible Targeted Genotypes: 3-6
Potential Combinations:
- Grazoprevir (MK-5172) + MK-3682 +/-
- Elbasvir (MK-8742) or MK-8408 +/-
- Ribavirin
Possible Length of Treatment: 8 – 24 weeks
Possible Daily Dose: 2 pills once daily
Step in Drug Approval Pipeline: Step 1 – Testing
Additional Information:
-
Efficacy and Safety of Grazoprevir (MK-5172) and MK-3682 with Elbasvir (MK-8742) or MK-8408 for Chronic Hepatitis C Virus (HCV) Genotype (GT) 3, GT4, GT5, and GT6 Infection (MK-3682-012)
Maker: Regulus
Treatment: RG-101
Targeted Genotypes: All
Treatment Description: RG-101 works with direct-acting antivirals to reduce viral load counts and lessen required treatment lengths.
Possible Length of Treatment: 4 – 12 weeks
Common Side Effects Reported in Clinical Trials:
- Headache
- Jaundice
- Tiredness (fatigue)
Step in Drug Approval Pipeline: Step 1 – Testing, Clinical trial hold (see below for more information)
Additional Information:
- Shorter treatment course potentially on the horizon for Hepatitis C patients
- RG-101 written by Regulus
- Regulus Reports FDA Clinical Hold of RG-101, June 27th, 2016
The information on this website is meant as a resource only and is not intended to replace qualified medical attention. Please seek advise and guidance from your health practitioners when considering your hep C treatment options.